东北制药：创新药迎突破 “双轮驱动”构筑新局

Core Viewpoint - Northeast Pharmaceutical is focusing on innovation-driven growth and deepening its core business, achieving significant results in R&D breakthroughs and quality improvement, establishing a collaborative development pattern of "R&D innovation, stable core business profitability, and efficient asset operation" [1][2] Group 1: Innovation Drug Business Breakthrough - The company has adopted a dual-driven strategy of "innovative drugs + generic drugs," enhancing its product matrix across various fields including neurology, digestion, endocrinology, oncology, and autoimmune diseases [2] - R&D investment has significantly increased, with a 95% year-on-year growth in R&D expenses in the first three quarters of this year, particularly targeting tumor immunotherapy [2] - The approval of DCTY0801 injection for clinical trials marks a key advancement in the company's innovative drug field, filling a gap in its oncology treatment portfolio and positioning it advantageously in the glioblastoma segment [2][3] Group 2: Steady Growth of Core Business - The core business of Northeast Pharmaceutical has shown steady growth, with a 27.54% year-on-year increase in net profit attributable to the parent company in the third quarter [4] - The company holds significant positions in various segments, being a major global supplier of vitamin C raw materials, and the largest producer of phosphomycin series products [4] - The product structure has been continuously improved, enhancing market competitiveness, with offerings spanning vitamins, anti-infection drugs, reproductive hormones, and more [4] Group 3: Financial and Operational Optimization - The development of the core business has supported the optimization of the operational structure and improved financial stability, with enhanced procurement efficiency and faster capital turnover [5] - The company aims to continue improving production organization, technical breakthroughs, and cost reduction, leveraging digital tools and R&D resources to enhance management efficiency [5] - The focus on product structure and R&D pipeline will strengthen the company's sustainable development capabilities and adaptability to industry trends and market competition [5]